Skip to main content
. 2020 Apr 20;13:1756284820905766. doi: 10.1177/1756284820905766

Figure 2.

Figure 2.

Frequency of TEAEs reported in at least 10.0% of patients in the RCT/extension teduglutide group.

Percentages calculated based on number of patients with a stoma (n = 45 for the RCT teduglutide group; n = 68 for the RCT/extension teduglutide group; n = 22 for the RCT placebo group).

AE grouping; the preferred terms in the AE groupings represent medically similar terms.

AE, adverse event; RCT, randomized controlled trial; TEAE, treatment-emergent AE.